企業プロフィール
Neumora Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- NMRA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
1.63 USD (+7.59%)
終値
最終更新: 2026年8月21日
324M USD
時価総額
株価変動の要因
As of Aug 21, 2026, NMRA closed up 7.59% at $1.63. No new same-company headline was identified in the current news window.
企業概要
Novel-Mechanism Therapeutics
Neumora Therapeutics develops medicines targeting novel biological mechanisms across brain and centrally mediated diseases. Its current clinical and preclinical portfolio includes programs in neuropsychiatric disorders, neurodegeneration, obesity, and cardiometabolic disease.
NMRA-215
NMRA-215 is an NLRP3 inflammasome inhibitor being developed for obesity and cardiometabolic disease. The program is advancing toward first-in-human development after favorable preclinical findings.
NMRA-511
NMRA-511 is a vasopressin 1a receptor antagonist being developed for agitation associated with Alzheimer's disease. Neumora is evaluating higher doses in a multiple-ascending-dose expansion cohort involving healthy elderly participants before moving into a patient-based Phase 2 study.
NMRA-898
NMRA-898 is an M4 muscarinic receptor positive allosteric modulator being developed for schizophrenia. The ongoing Phase 1 multiple-ascending-dose study includes both healthy volunteers and patients with stable schizophrenia.
今後のカタリスト
- Phase 1 multiple-ascending-dose data for NMRA-898 in the second half of 2026.
- Submission of an IND for NMRA-215 in the fourth quarter of 2026.
- Multiple-ascending-dose expansion data for NMRA-511 in the fourth quarter of 2026.
- Initiation of the Phase 1 study of NMRA-215 by the end of 2026.
- Initiation of the Phase 2 study of NMRA-511 in Alzheimer's disease agitation by the end of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。